NAD+ Complete Guide: Coenzyme Biology, Decline, and Delivery Routes

NAD+ has two main jobs. As a redox carrier it shuttles electrons between metabolic pathways — glycolysis, the citric acid cycle, oxidative phosphorylation — accepting electrons (becoming NADH) and giving them back as ATP production runs. Without NAD+ available in its oxidised form, the energy-producing pathways stall.^[1][2]

Its second job is to be consumed. Sirtuins — a family of seven mammalian deacetylase enzymes (SIRT1 through SIRT7) — strip acetyl groups from histones and other regulatory proteins, and they use up an NAD+ molecule with every reaction. PARP enzymes do something similar when DNA damage occurs: PARP1 detects a broken strand and consumes NAD+ to lay down poly-ADP-ribose chains that recruit repair machinery.^[1][6]

The published mechanistic picture is that sirtuins and PARP draw from the same NAD+ pool. When DNA damage rises with age, PARP activity rises with it, and the available NAD+ for sirtuin work falls. That competition is part of why NAD+ depletion shows up in aging tissue.^[6][1]

Multiple peer-reviewed studies report that tissue NAD+ concentrations decline with age in rodents, and human tissue and blood measurements support a similar pattern, though the magnitude differs across tissues and methods. Verdin's 2015 Science review consolidated this as the mechanistic backbone for the 'NAD+ in aging' story — coupling decline to sirtuin biology, mitochondrial function, and neurodegeneration.^[1][2]

The honest framing: NAD+ decline is consistently observed, but the magnitude, the rate, and the precise contribution of synthesis-versus-consumption are still active research questions. The Cleveland Clinic primer summarises the consumer-facing version of this without overstating: levels fall, restoring them is studied, the clinical-outcome question is open.^[3][2]

Reading age-related NAD+ decline as 'low NAD+ causes aging' is the kind of reverse inference that science writers warn against. The defensible reading is that NAD+ is one of several cellular variables that shifts with age, and the question 'does restoring it improve outcomes in humans' is what current clinical research is trying to answer.^[2][9]

Three formats dominate the conversation, and they are not interchangeable. They differ in pharmacokinetics, regulatory status, and what is actually inside the vial.^[2][5]

| Format | What's in the vial | Route | Typical research framing | EU regulatory status | | --- | --- | --- | --- | --- | | IV NAD+ infusion | NAD+ coenzyme dissolved in saline | Intravenous, slow infusion | Direct repletion; observational case-series in fatigue, recovery, longevity contexts | Compounding-pharmacy / clinic prescribed; not an EMA-authorised medicine | | Subcutaneous NAD+ | NAD+ coenzyme in injectable buffer | Subcutaneous injection | Slower, lower-peak delivery; favoured in longevity protocols for sustained exposure | Not EMA-authorised; research-peptide quality conventions are applied to handling | | Oral NR (nicotinamide riboside) | Nicotinamide riboside precursor | Oral capsule | Raises blood NAD+ metabolites in published human studies | EU novel-food authorised in food-supplement form | | Oral NMN (nicotinamide mononucleotide) | Nicotinamide mononucleotide precursor | Oral capsule | Raises blood NAD+ metabolites in published human studies | Regulatory status varies by EU member state; not uniformly classified |^[5][4][7]

Why clinical longevity protocols often favour injection over oral: direct NAD+ skips the precursor-conversion step, and pharmacokinetic models in published research suggest that oral precursors raise NAD+ metabolites systemically but reach intracellular NAD+ unevenly across tissues. Subcutaneous delivery has been adopted in clinic protocols as a middle ground — slower absorption than IV, fewer infusion-suite logistics.^[2][5]

The published evidence does not yet say one format is decisively 'better' for any clinical longevity endpoint in humans. It does say the four formats produce different blood and tissue pharmacokinetics, and any honest comparison should start from that, not from which one a clinic prefers to bill for.^[5][4]

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are the most studied oral NAD+ precursors. Published human pharmacokinetic studies show that oral NR raises whole-blood NAD+ levels in a dose-dependent way, and small clinical trials have tested NR in conditions ranging from heart failure to peripheral neuropathy, with mixed and often early-stage results.^[5][4]

NMN human trials are smaller and newer. Pharmacokinetic data confirm oral NMN raises plasma NAD+ metabolites; clinical-outcome data in domains like insulin sensitivity and cardiovascular function exists in early-phase form but is not yet established by large, long-duration randomised trials.^[5][9]

The honest reading: 'oral precursor raises blood NAD+ metabolites' is well-supported. 'Oral precursor extends healthspan or treats a specific disease' is still being tested. The Cleveland Clinic primer for consumers makes the same distinction.^[3][4]

Three reasons turn up consistently in clinic-protocol writing and peer-reviewed pharmacokinetic studies. First, direct NAD+ bypasses precursor conversion — every metabolic step adds a place where individual variation can change how much NAD+ actually reaches cellular pools. Second, blood-pool kinetics for direct NAD+ peak higher than for equivalent oral precursor doses in published comparisons. Third, intracellular tissue distribution differs between precursor and direct NAD+ in animal models.^[2][5]

What that does not mean: injection is not 'better' as a categorical statement. It means the published pharmacokinetic profile differs in defensible, measurable ways, and longevity-clinic protocols have made an evidence-informed but not yet trial-validated bet on direct delivery as a result. The randomised-trial evidence for clinical-outcome superiority of injection over oral precursor in humans does not yet exist at large scale.^[2][9]

Subcutaneous NAD+ specifically gets selected in many clinic protocols as a compromise: lower peak than IV, no infusion-suite logistics, more sustained exposure than precursor pills. That is a practical workflow choice, not a published clinical-superiority claim.^[2]

Direct NAD+ — as IV or subcutaneous injection — is not an EMA-authorised medicine for any indication. There is no EPAR for NAD+ as a marketed therapy. Clinical use is compounded by pharmacies or administered in private longevity clinics, and consumer purchase of injectable NAD+ does not pass through the medicinal-product regulatory framework.^[7][8]

Oral NR has a clearer status: nicotinamide riboside chloride was authorised as a novel food in the EU under the Novel Food Regulation, which lets it appear in food supplements within specified limits. Oral NMN status varies between EU member states — some classify it as a food supplement, others have flagged it as needing novel-food assessment, and the regulatory picture is actively evolving.^[7]

The buyer-relevant version: a 'NAD+ supplement' page may sell oral NR (clearly regulated as food supplement), oral NMN (varies by country), or injectable NAD+ (not regulated as a medicine). Those are three different regulatory categories. Conflating them is the most common error in NAD+ marketing.^[7][9]

Look for category honesty first. Does the page say NAD+ is a coenzyme, not a peptide? Does it distinguish between IV, subcutaneous, NR, and NMN — and explain the pharmacokinetic and regulatory differences? Does it state that direct NAD+ is not an EMA-authorised medicine, and that consumer use happens outside the medicinal-product framework?^[10][11][7]

Then quality. For injectable NAD+: batch-specific identity (NMR or MS), purity, endotoxin and sterility documentation if it is sold for injection. For oral precursors: identity, purity, and clear ingredient listing under the relevant food-supplement framework. ISO/IEC 17025 lab signal for the analytical method.^[10][11]

Finally, the editorial test. A page that promises 'reverse aging' is not engaging the published evidence honestly. A page that explains the mechanism, distinguishes injection from precursor, and acknowledges that human clinical-outcome data is still early — that is the writing built for careful readers.^[1][3][2]